Evidence map›Paper›PMID 39895905›Full record

ArticleLancet regional health. Americas2025

Effectiveness of late and very late antivenom administration on recovery from snakebite-induced coagulopathy in French Guiana: a population-based study.

Jean Marc Pujo, Stephanie Houcke, Guy Roger Lontsi Ngoulla, Vivian Laurent, Boubacar Signaté, Rémi Mutricy, Alexis Frémery, Flaubert Nkontcho, Ibtissem Ben Amara, José María Gutiérrez and 2 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jean Marc PujoEmergency Department, Cayenne General Hospital, Cayenne, French Guiana.
Stephanie HouckeIntensive Care Unit, Cayenne General Hospital, Cayenne, French Guiana.
Guy Roger Lontsi NgoullaIntensive Care Unit, Cayenne General Hospital, Cayenne, French Guiana.
Vivian LaurentEmergency Department, Cayenne General Hospital, Cayenne, French Guiana.
Boubacar SignatéEmergency Department, Cayenne General Hospital, Cayenne, French Guiana.
Rémi MutricyEmergency Department, Cayenne General Hospital, Cayenne, French Guiana.
Alexis FrémeryEmergency Department, Cayenne General Hospital, Cayenne, French Guiana.
Flaubert NkontchoPharmacy Department, Cayenne General Hospital, Cayenne, French Guiana.
Ibtissem Ben AmaraTropical Biome and Immunopathology CNRS UMR-9017, Inserm U 1019, Université de Guyane, Cayenne, French Guiana.
José María GutiérrezInstituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.
Dabor ResiereIntensive Care Unit, Martinique University Hospital, Fort de France, Martinique.
Hatem KallelTropical Biome and Immunopathology CNRS UMR-9017, Inserm U 1019, Université de Guyane, Cayenne, French Guiana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Snakebite (SB) envenoming is an acute emergency requiring early care delivery. However, sometimes, patients can take several hours before receiving antivenom (AV). We conducted this study to assess the effectiveness of antivenom in the recovery of clotting parameters in patients consulting tardily after SB envenoming in French Guiana. The primary endpoint of our study was to investigate the time needed from SB to recovery from SB-induced coagulopathy. The secondary endpoint was to investigate the time needed from AV administration to recovery from SB-induced coagulopathy in patients receiving AV (late or very late administration). Methods: This prospective observational study was conducted in the Intensive Care Unit (ICU) of Cayenne General Hospital between January 2016 and September 2023. We included all patients hospitalized for SB envenoming who either did not receive AV or received it more than 6 h after SB. We excluded patients who received antivenom in less than 6 h from the SB and those who received incomplete AV doses. Findings: We included 58 patients in the No AV group, 51 in the late AV group (6 h ≤ AV < 12 h), and 50 in the very late AV group (AV≥12 h). The median age of patients was 42 years (IQR: 29-53), 65.4% were male and 34.6% were female (104 and 55 out of 159 patients) without difference regarding the demographic parameters between groups. Data regarding ethnicity was not available. The median time from SB to AV was 8.5 h (IQR: 6.9-10) in the late AV group and 21.1 h (IQR: 16.7-27.4) in the very late AV group (p < 0.001). The time from SB to normal clotting parameters was shorter in patients receiving late AV than in those receiving very late AV and those not receiving AV. No differences were observed in the time from SB and recovery of fibrinogen and activated partial thromboplastin time (aPTT) between very late AV and no AV. However, the International Normalized Ratio (INR) recovery was shorter in the very late AV group than in the no AV group. On the other hand, the time from AV to normal fibrinogen was shorter in patients receiving very late AV than in patients receiving late AV (Log-Rank = 0.020). Meanwhile, the time from AV to normal INR or normal aPTT was similar in patients receiving very late AV compared to patients receiving late AV (Log-Rank = 0.722 and 0.740, respectively). Interpretation: Late AV administration effectively reverses coagulopathic manifestations after SB envenoming. However, very late AV administration did not improve the correction of some clotting parameters when compared to patients not receiving AV. Our findings could be explained by the combination of venom toxicokinetics and the kinetics of the synthesis of clotting factors. Funding: No funding.

Indexed as

Antivipmyn Tri®Bothrops atroxClotting timeFrench GuianaSnakebite envenoming

Identifiers

PMID39895905
PMCPMC11787608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.